Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 213,653 shares, an increase of 246.6% from the May 31st total of 61,636 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average trading volume of 333,674 shares, the short-interest ratio is currently 0.6 days.
Azitra Stock Performance
Shares of AZTR traded up $0.01 on Monday, reaching $0.18. 4,563,900 shares of the company’s stock traded hands, compared to its average volume of 12,150,128. The stock’s 50 day simple moving average is $0.21 and its two-hundred day simple moving average is $0.23. Azitra has a 52-week low of $0.10 and a 52-week high of $1.83.
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.24). As a group, sell-side analysts forecast that Azitra will post -0.25 earnings per share for the current year.
About Azitra
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Read More
- Five stocks we like better than Azitra
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
